CJC-1295

At a glance

Overview

The original CJC-1295 combines a modified GHRH sequence with a drug-affinity complex that allows binding to circulating albumin. This design extends exposure substantially compared with short-lived GHRH fragments. Early clinical development measured growth hormone and IGF-1 rather than long-term patient outcomes. Commercial terminology creates a separate problem: products described as CJC-1295 without DAC commonly refer to a modified GHRH fragment with different pharmacokinetics. Results from albumin-binding CJC-1295 cannot simply be assigned to that preparation. The compound has no FDA-approved therapeutic indication, and online claims about fat loss or anti-aging exceed the direct clinical evidence.

Supporting sources [1] [2] [3]

How it works

CJC-1295 stimulates GHRH receptors on pituitary somatotrophs, increasing release of growth hormone and downstream IGF-1. Albumin binding prolongs its residence in circulation. In early human studies, increased basal and overall GH output could coexist with recognizable pulsatile secretion. Demonstrating that this endocrine pathway responds is target-engagement evidence; it does not establish that chronically raising these hormones produces a net health benefit.

Supporting sources [1] [2] [3]

What did human studies actually show?

Two early randomized studies found prolonged increases in circulating GH and IGF-1 after CJC-1295. A separate physiology study found preservation of GH pulsatility despite increased overall secretion. These endpoints establish biological activity. They do not demonstrate fewer fractures, stronger muscles, improved recovery, reduced disability, or longer life.

Supporting sources [1] [2]

Known concerns and unknown long-term effects

FDA identifies increased heart rate and systemic vasodilatory reactions among serious events associated with CJC-1295. It also highlights possible immune reactions and difficulties characterizing peptide impurities. The short early studies cannot reliably exclude uncommon harms or determine the safety of prolonged use, especially in people with metabolic disease.

Supporting sources [3]

Approval and compounding are different questions

CJC-1295 has no FDA-approved medicine. A nomination for a compounding list, a prescription from a clinic, and a vendor certificate are separate from approval demonstrating a particular product’s safety and effectiveness. FDA’s safety review describes limited clinical information; the current compounding-policy category should not be treated as an efficacy rating.

Supporting sources [3]

Can CJC-1295 evidence be applied to combinations?

No controlled benefit can be assumed for a CJC-1295–ipamorelin mixture from separate hormone-response studies. The exact compounds, exposure, interactions, and clinical outcome all matter. Combining a GHRH analog with a ghrelin-receptor agonist changes the intervention and requires its own evidence, even when both can stimulate GH.

Supporting sources [1] [2] [3]